Owen Hughes - XOMA Corp CEO Director
| XOMA Stock | USD 33.17 0.71 2.10% |
CEO
Owen Hughes is CEO Director of XOMA Corp
| Age | 49 |
| Address | 2200 Powell Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 204 7200 |
| Web | https://xoma.com |
Owen Hughes Latest Insider Activity
Tracking and analyzing the buying and selling activities of Owen Hughes against XOMA Corp stock is an integral part of due diligence when investing in XOMA Corp. Owen Hughes insider activity provides valuable insight into whether XOMA Corp is net buyers or sellers over its current business cycle. Note, XOMA Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell XOMA Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Owen Hughes over a week ago Disposition of 21881 shares by Owen Hughes of XOMA Corp at 29.95 subject to Rule 16b-3 |
XOMA Corp Management Efficiency
The company has return on total asset (ROA) of (0.0554) % which means that it has lost $0.0554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3141) %, meaning that it created substantial loss on money invested by shareholders. XOMA Corp's management efficiency ratios could be used to measure how well XOMA Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.18. In addition to that, Return On Capital Employed is expected to decline to -0.2. At present, XOMA Corp's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 68.2 M, whereas Other Current Assets are forecasted to decline to about 610.9 K.Similar Executives
| Found 9 records | CEO Age | ||
| Barbara MD | Tango Therapeutics | 67 | |
| Joshua Brumm | Dyne Therapeutics | 46 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| Scott Struthers | Crinetics Pharmaceuticals | 61 | |
| BAO BCh | Eliem Therapeutics | 48 | |
| Andrew MBA | C4 Therapeutics | 53 | |
| William MD | Passage Bio | 51 | |
| Kevin Koch | Edgewise Therapeutics | 64 | |
| Nevan JD | Rezolute | 57 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0554 |
XOMA Corp Leadership Team
Elected by the shareholders, the XOMA Corp's board of directors comprises two types of representatives: XOMA Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XOMA. The board's role is to monitor XOMA Corp's management team and ensure that shareholders' interests are well served. XOMA Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XOMA Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brad Sitko, Chief Officer | ||
| MS MBA, CEO Chairman | ||
| Owen Hughes, CEO Director | ||
| Thomas Burns, CFO and VP of Fin. |
XOMA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XOMA Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0554 | ||||
| Profit Margin | (1.39) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 341.54 M | ||||
| Shares Outstanding | 11.78 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 65.60 % | ||||
| Number Of Shares Shorted | 173.26 K | ||||
| Price To Earning | 30.78 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XOMA Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XOMA Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xoma Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xoma Corp Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XOMA Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade XOMA Stock refer to our How to Trade XOMA Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XOMA Corp. If investors know XOMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XOMA Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.37 | Earnings Share (3.07) | Revenue Per Share 1.862 | Quarterly Revenue Growth 7.671 | Return On Assets (0.06) |
The market value of XOMA Corp is measured differently than its book value, which is the value of XOMA that is recorded on the company's balance sheet. Investors also form their own opinion of XOMA Corp's value that differs from its market value or its book value, called intrinsic value, which is XOMA Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XOMA Corp's market value can be influenced by many factors that don't directly affect XOMA Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XOMA Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if XOMA Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XOMA Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.